Polypharmacy Among Prescription Drug Users
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Substance Use Resources for Grades 7-12
1 Substance Use Resources for Grades 7-12 Online Resource Library Search: https://www.voa-dakotas.org/resource-library Addiction: page 1 Alcohol: page 1 Drugs: page 4 Vaping/tobacco: page 10 Addiction Addiction and the Human Brain o DVD, 2006, HRM, 27 minutes, Grades 7-12 o Drug addiction is a disease of the brain and teens are at highest risk for acquiring this disease. This DVD explains the changes to the brain caused by prolonged use of drugs and shows why voluntary drug use eventually becomes involuntary and compulsive. Studies indicate that drugs affect the developing brain more than the brain of someone more mature, thus putting teens at a higher risk of addiction. Interviews with recovering teen addicts, an addiction counselor, and brain experts and researchers provide sobering considerations to viewers. Pre- and Post-tests are included. How Addiction Hijacks the Brain o DVD, 2016, HRM, CC, 24 minutes, Grades 7-College o This film drives home the message that drug and alcohol addiction are a disease of the brain and that teens are at highest risk for acquiring this disease. Leading scientists detail how drugs like heroin, nicotine, cocaine and marijuana change the brain, subvert the way it registers pleasure, and corrupt learning and motivation. Young recovering addicts provide a human face to the effects of drugs and alcohol as they describe how addiction involves intense craving for a drug and loss of control over its use. Viewers also learn that the brain’s plasticity, or ability to change, offers hope for addicts that they can turn their lives around. -
Polypharmacy and the Senior Citizen: the Influence of Direct-To-Consumer Advertising
2021;69:19-25 CLINICAL GETRIATRICS - ORIGINAL INVESTIGATION doi: 10.36150/2499-6564-447 Polypharmacy and the senior citizen: the influence of direct-to-consumer advertising Linda Sperling, DHA, MSN, RN1, Martine B. Fairbanks, Ed.D, MA, BS2 1 College of nursing, University of Phoenix, Arizona, USA; 2 College of doctoral studies, University of Phoenix, Arizona, USA Background. Polypharmacy, or taking five or more medications dai- ly, can lead to poor medication compliance and an increased risk for adverse drug-to-drug interactions that may eventually lead to death. The study was designed to explore the questions of how age, the re- lationship between the physician and patient, and television, radio, magazines and modern electronic technology, such as the Internet, affect patients’ understanding of their medical care. Two main areas addressed in this research study included the pharmaceutical indus- try’s influence on consumer decisions to ask a physician for a particular medication, and the prescribing practices of the physician. Methods. This qualitative phenomenological study began with pre- screening volunteer residents in a nursing home to discover poten- tial participants who met the criteria of using five or more medicines daily. We then interviewed 24 participants who met the criteria, using semi-structured interview questions. Results. Four core themes emerged from this study: professional trust, professional knowledge, communication deficit, and direct-to-consum- Received: April 30, 2020 er advertising. Participants reported trusting their doctors and taking Accepted: November 2, 2020 medications without question, but most knew why they were taking the Correspondence medications. Participants also reported seeing ads for medications, but Linda Sperling DHA, MSN, RN only one reported asking a physician to prescribe the medication. -
Opioid Weaning Guidance Document Primary Care GENERAL CONSIDERATIONS: 1
Opioid Weaning Guidance Document Primary Care GENERAL CONSIDERATIONS: 1. Determine if the goal is a dose reduction or complete discontinuation of agent(s). 2. Weans should occur gradually to minimize the risk of withdrawal symptoms. Weaning opioids may take 6 months or more depending on the total opioid dose and the individual patient’s response to the opioid wean. There is no need to rush this process as this may only cause more distress for the patient. 3. Optimize non-opioid pain management strategies. This link provides options for non-opioid strategies: https://www.cdc.gov/drugoverdose/pdf/alternative_treatments-a.pdf a. Recommend implementing one non-opioid agent at a time b. Evaluate and discontinue any agents that are ineffective c. Do not exceed maximum recommended doses or combine multiple agents from the same medication class d. Avoid use of benzodiazepines or any sedative hypnotic agents 4. Set expectations and functional goals with patient prior to initiation of the opioid wean. 5. Educate patient on the change in opioid tolerance over time during the opioid wean and risk for overdose if they resume their starting dose or a previously stable higher dose. Discuss/prescribe naloxone to minimize the risk of overdose. 6. Screen for and treat any untreated/under-treated depression. Depression may make the weaning process more challenging. MORPHINE EQUIVALENT DOSE CALCULATOR: 1. Link to calculator: http://www.agencymeddirectors.wa.gov/Calculator/DoseCalculator.htm 2. This calculator can be utilized to determine the current morphine equivalent dose your patient is receiving at baseline. If the goal is for opioid dose reduction, this calculator can also be used to determine your goal “ending” dose. -
Qato Et Al, “Changes in Prescription and Over-The-Counter Medi
Polypharmacy: time to get beyond numbers Invited commentary on: Qato et al, “Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011” and Jou et al, “Non-disclosure of complementary and alternative medicine (CAM) use to usual care providers: Findings from the 2012 National Health Interview Survey” Michael A. Steinman, MD Division of Geriatrics, University of California, San Francisco and the San Francisco VA Health Care System Word count: 1023 References: 7 Support: Supported by grants from the National Institute on Aging (K24-AG049057-01 and P30- AG044281) Acknowledgement / Disclosure: Dr. Steinman is a consultant for iodine.com, an internet start-up company. Corresponding author: Michael A. Steinman, MD 4150 Clement St, VA Box 181G San Francisco, CA 94121 [email protected] When I tell someone that I am a geriatrician, I often get the same response. I am told half- jokingly that the person needs my services. Then, I am regaled with a story of how the person’s older parent, grandparent, or spouse is prescribed an enormous number of medications, thinks they might be causing problems, and doesn’t know what to do about it. It is this view of polypharmacy that often dominates patients’, and increasingly clinicians’, experience of medication use. This skeptical perspective is largely justified. The number of medications a person uses is by far the strongest risk factor for medication-related problems. As the number of medications rises, adverse drug reactions become more common. Adherence worsens. Out-of-pocket costs rise. -
Polypharmacy in the Elderly Educational Format Faculty Expertise Required Expertise in the Field of Study
2019 AAFP FMX Needs Assessment Body System: Geriatrics Session Topic: Polypharmacy in the Elderly Educational Format Faculty Expertise Required Expertise in the field of study. Experience teaching in the field of study is desired. Preferred experience with audience Interactive REQUIRED response systems (ARS). Utilizing polling questions and Lecture engaging the learners in Q&A during the final 15 minutes of the session are required. Expertise teaching highly interactive, small group learning environments. Case-based, with experience developing and Problem- teaching case scenarios for simulation labs preferred. Other Based workshop-oriented designs may be accommodated. A typical OPTIONAL Learning PBL room is set for 50-100 participants, with 7-8 each per (PBL) round table. Please describe your interest and plan for teaching a PBL on your proposal form. Learning Objective(s) that will close Outcome Being Professional Practice Gap the gap and meet the need Measured Family physicians have 1. Use evidence-based criteria (e.g. Learners will gaps in knowledge and BEERS, STOPP, START) to submit written performance in evaluating evaluate for potentially adverse drug commitment to for potentially adverse drug events, among elderly patients change statements events, among elderly receiving multiple medications. on the session patients receiving multiple 2. Develop a systematic approach, evaluation, medications. including applicable REMS, to indicating how Family physicians have managing elderly patients with they plan to gaps in knowledge and -
Epidemic of Prescription Drug Overdose in Ohio
EPIDEMIC OF PRESCRIPTION There were more deaths in 2008 and 2009 in Ohio from D RUG OVERDOSE IN OHIO unintentional drug overdose than from DID YOU KNOW? motor vehicle In 2007, unintentional drug poisoning became the leading crashes! cause of injury death in Ohio, surpassing motor vehicle crashes and suicide for the first time on record. This trend continued in 2009. (See Figure 1) Among the leading causes of injury death (see below), unintentional poisonings increased from the cause of the fewest number of annual deaths in 1999 (369 deaths) to the greatest in 2009 (1,817).i (See Figure 2) From 1999 to 2009, Ohio’s death rate due to unintentional drug poisonings increased 335 percent, and the increase in deaths has been driven largely by prescription drug overdoses. In Ohio, there were 327 fatal unintentional drug overdoses in 1999 growing to 1,423 annual deaths in 2009. On average, from 2006 to 2009, approximately four people died each day in Ohio due to drug overdose.v Figure 1. Number of deaths from MV traffic Figure 2 . Percent change in the number of deaths for and unintentional drug poisonings by year, the leading causes of injury, Ohio 1999-20091,2 Ohio, 2000-20091,2 1800 all unintentional 39% 1600 firearm related 15% 1400 1200 homicide 34% 1000 unintentional suicide 17% 800 poisoning 600 unintentional poisoning 301% unt MV traffic Number of deathsNumber 400 unt MV traffic -31% 200 unintentional falls 100% 0 -100% 0% 100% 200% 300% 400% Percent change from 2000-2009 Year 1Source: Ohio Department of Health, Office of Vital Statistics; 2 Unintentional Poisoning includes non-drug and drug-related poisoning. -
Suicides Due to Alcohol And/Or Drug Overdose
Suicides Due to Alcohol and/or Drug Overdose A Data Brief from the National Violent Death Reporting System National Center for Injury Prevention and Control Division of Violence Prevention Background Suicide occurs when a person ends his or her own life. It is the 11th leading cause of death among NVDRS is a state-based system for Americans, and every year more than 33,000 providing detailed information about people end their own lives. Suicide is found in violent deaths, such as when, where, every age, racial, and ethnic group to differing and how they happen and other possible degrees (1). contributing factors. This information can be used to monitor homicides and There are a number of factors that increase the suicides and design and evaluate prevention likelihood a person will take his or her own life; strategies. Benefits of NVDRS include the one of these is abusing substances such as alcohol following: and drugs (1). Alcohol and drug abuse are second only to depression and other mood disorders as• Linked records describing the detailed the most frequent risk factors for suicidal behavior circumstances that may contribute to a (2, 3). Alcohol and some drugs can result in a loss violent death of inhibition, may increase impulsive behavior, can lead to changes in the brain that result in • Identification of violent deaths occurring depression over time, and can be disruptive to together to help describe the circumstance relationships— resulting in alienation and a loss of multiple homicides or homicide- of social connection (4). Furthermore, excessive suicides acute drug and/or alcohol ingestion could result in death. -
The Biden-Harris Administration's Statement of Drug Policy Priorities
EXECUTIVE OFFICE OF THE PRESIDENT OFFICE OF NATIONAL DRUG CONTROL POLICY Washington, DC 20503 The Biden-Harris Administration’s Statement of Drug Policy Priorities for Year One The overdose and addiction crisis has taken a heartbreaking toll on far too many Americans and their families. Since 2015, overdose death numbers have risen 35 percent, reaching a historic high of 70,630 deaths in 2019.1 This is a greater rate of increase than for any other type of injury death in the United States.2 Though illicitly manufactured fentanyl and synthetic opioids other than methadone (SOOTM) have been the primary driver behind the increase, overdose deaths involving cocaine and other psychostimulants, like methamphetamine,3 have also risen in recent years, particularly in combination with SOOTM. New data suggest that COVID-19 has exacerbated the epidemic,4, 5 and increases in overdose mortality6 have underscored systemic inequities in our nation’s approach to criminal justice and prevention, treatment, and recovery. President Biden has made clear that addressing the overdose and addiction epidemic is an urgent priority for his administration. In March, the President signed into law the American Rescue Plan, which appropriated nearly $4 billion to enable the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration to expand access to vital behavioral health services. President Biden has also said that people should not be incarcerated for drug use but should be offered treatment instead. The President has also emphasized the need to eradicate racial, gender, and economic inequities that currently exist in the criminal justice system. -
Polypharmacy & Deprescribing
Lauren W. Mazzurco, DO Polypharmacy & Eastern Virginia Medical School Deprescribing [email protected] • I have no conflicts of interest to disclose Objectives • Describe the concept and impact of polypharmacy in older adults • Review the benefits of and potential barriers to deprescribing • Describe the process of rational deprescribing and demonstrate practical strategies of application to clinical scenarios https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-Conditions/Downloads/2012Chartbook.pdf Scope of the problem • 30% of patients >65 are prescribed >5 medications • ~1 in 5 medications in older adults may be inappropriate • Single most predictor of harm is # of medications 1. QatoDM,AlexanderGC,ContiRM,JohnsonM, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878. 2. RougheadEE,AndersonB,GilbertAL. Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern Med J. 2007;37(6):402-405 3. SteinmanMA,MiaoY,BoscardinWJ,Komaiko KD, Schwartz JB. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med. 2014;29(10):1379-1386 4. BudnitzDS,LovegroveMC,ShehabN,Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365 (21):2002-2012. Quality Value = Cost http://ihpi.umich.edu/news/older-americans-don’t-get-–-or-seek-–-enough-help-doctors-pharmacists-drug-costs- poll-finds. Accessed -
April 9, 2021 Addiction in the News
UC CAR Weekly Newsletter 4.9.2021 Welcome to the weekly newsletter from the Center for Addiction Research! Each newsletter includes highlights from addiction in the news topics, active funding opportunities offered by NIDA/NIAAA, and information about any new publications from CAR members. Please email Jen Rowe ([email protected]) to change your communication preferences. Thank you. Thank you for your interest in the Center for Addiction Research - our mission is to accelerate scientific progress in the prevention and treatment of substance use disorders and their consequences by fostering research collaborations across: 1) UC departments, colleges, and centers including Cincinnati Children’s Hospital Medical Center; 2) Local, regional, and state community and governmental partners; and 3) Other academic institutions and industry." April 9, 2021 Addiction in the News UC/ Regional News Opinion: Our society often punishes individuals struggling with addiction The recent settlement announced between the state of Ohio and consulting business McKinsey & Co. for the firm's role in creating and fueling the opioid epidemic is a perfect example of how we unfairly punish Ohioans dealing with substance-use disorder while allowing the engineers of this crisis to escape with just a slap on the wrist. More than 200,000 lives have been lost to the opioid… The Opioid Crisis Was America’s Epidemic Before COVID. Research Suggests that Overdoses Hurt Student Achievement Long before the emergence of COVID-19, the United States was struggling to contain a years-long opioid crisis that took tens of thousands of lives every year. Now, with Oxycontin manufacturer Purdue Pharma still negotiating billion-dollar penalties for its role in the two-decade drug epidemic, experts have begun taking the measure of its impact on student learning. -
SAMHSA Opioid Overdose Prevention TOOLKIT
SAMHSA Opioid Overdose Prevention TOOLKIT Opioid Use Disorder Facts Five Essential Steps for First Responders Information for Prescribers Safety Advice for Patients & Family Members Recovering From Opioid Overdose TABLE OF CONTENTS SAMHSA Opioid Overdose Prevention Toolkit Opioid Use Disorder Facts.................................................................................................................. 1 Scope of the Problem....................................................................................................................... 1 Strategies to Prevent Overdose Deaths.......................................................................................... 2 Resources for Communities............................................................................................................. 4 Five Essential Steps for First Responders ........................................................................................ 5 Step 1: Evaluate for Signs of Opioid Overdose ................................................................................ 5 Step 2: Call 911 for Help .................................................................................................................. 5 Step 3: Administer Naloxone ............................................................................................................ 6 Step 4: Support the Person’s Breathing ........................................................................................... 7 Step 5: Monitor the Person’s Response .......................................................................................... -
MDMA (Ecstasy) Related Deaths (2006-2012)
BC Coroners Service MDMA (Ecstasy) Related Deaths 2006-2012 This report summarizes all cases from 2006 to 2012 for which toxicological testing was positive for Methylenedioxymethamphetamine (MDMA, also known as Ecstasty), and for which the investigating coroner determined that MDMA was relevant to the death. The BCCS operates in a live database environment. The data are considered preliminary until all investigations have been completed. Data are subject to change, and are not directly comparable to published counts from previous years. MDMA-Related Deaths, 2006-2012 Relevant to Death 2006 2007 2008 2009 2010 2011 *2012 Yes 7 13 23 21 18 13 5 Under Investigation* - - - - - 1 6 Total 7 13 23 21 18 14 11 * Relevance of MDMA detected by toxicological testing is yet to be determined for cases which are under investigation MDMA-Related Deaths by Classification, 2006-2012 Classification 2006 2007 2008 2009 2010 2011 *2012 % Accidental 7 12 21 19 15 13 8 88.8 Natural - 1 1 - 1 - - 2.8 Suicide - - 1 1 1 1 - 3.7 Undetermined - - - 1 1 - 3 4.7 Total 7 13 23 21 18 14 11 100 Ministry of Justice January 31, 2013 Office of the Chief Coroner Metrotower II, Suite 800 4720 Kingsway, Burnaby BC V5H 4N2 Phone: 604 660-7745 Fax: 604 660-7766 Page 1 of 5 BC Coroners Service MDMA (Ecstasy) Related Deaths 2006-2012 MDMA-Related Deaths by Means of Death, 2006-2012 Means of Death 2006 2007 2008 2009 2010 2011 2012 % Drug Overdose* 3 7 11 16 13 13 11 69.2 Motor Vehicle Incident 3 2 7 3 1 - - 15.0 Fall - 2 3 - 3 1 - 8.4 Natural Disease - 1 1 - 1 - - 2.8 Drowning